PAUL CORN to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications PAUL CORN has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.151
-
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med. 2021 04; 10(7):2341-2349.
Score: 0.121
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.030